News >

Capitalizing on Integrative Immunotherapy in Ovarian Cancer

Caroline Seymour
Published: Monday, Apr 08, 2019

Dmitriy Zamarin, MD, PhD

Dmitriy Zamarin, MD, PhD
In advanced ovarian cancer, initial interest with immunotherapy focused on single-agent PD-1/PD-L1 blockade. Due to disappointing activity, however, investigators have turned to the use of combination strategies with chemotherapy, angiogenesis agents, and PARP inhibition with some success, explained Dmitriy Zamarin, MD, PhD.

State of the Science Summit™ on Ovarian Cancer and Soft Tissue Sarcoma, Zamarin, a medical oncologist at Memorial Sloan Kettering Cancer Center, discussed ongoing research regarding immunotherapy and synergistic strategies also under investigation in advanced ovarian cancer.

OncLive®: What is the outlook for immunotherapy in advanced ovarian cancer?

Zamarin: There have been several studies utilizing various immunotherapies, namely immune checkpoint inhibitors in newly diagnosed and advanced ovarian cancer. Most of the studies have been done primarily in patients with advanced platinum-resistant disease. The response rates we have seen so far have been rather disappointing. Initially, there was enthusiasm for these drugs, but to date the single agent PD-1/ PD-L1 inhibitors have shown response rates of approximately 9% to 10%. We still don't have a good biomarker of response.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication